One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response

被引:58
作者
Faber, L.
Welge, D.
Fassbender, D.
Schmidt, H. K.
Horstkotte, D.
Seggewiss, H.
机构
[1] Ruhr Univ Bochum, Heart & Diabetes Ctr, Dept Cardiol, D-32545 Bad Oeynhausen, Germany
[2] Leopoldina Hosp, D-97422 Schweinfurt, Germany
关键词
hypertrophic obstructive cardiomyopathy; percutaneous septal ablation; left ventricular outflow tract gradient; myocardial contrast echocardiography;
D O I
10.1007/s00392-007-0578-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim The aim of this study was to analyze hemodynamic and clinical outcome in a cohort of 312 patients who were followed up over a period of 12 months after alcohol septal ablation (PTSMA) for symptomatic hypertrophic obstructive cardiomyopathy (HOCM). Methods and results PTSMA was intended in 337 patients with HOCM (mean age: 54 +/- 15 years), with 312 procedures completed by injection of 2.8 +/- 1.2 ml of alcohol. In 25 patients (8%) the intervention was aborted, mostly because of contrast echocardiographic findings. In the 312 patients who received alcohol, permanent pacing was necessary in 22 cases (7%); and in-hospital mortality was 1.3% (four patients). During follow-up, contact to six patients (2%) was lost, and three additional patients (1%) died. The 299 patients who either underwent non-invasive reassessment in our institution or transmitted follow-up data from their local physician formed the study population. Improvement in symptoms was reported by 272 patients (91%). Mean NYHA functional class was reduced from 2.9 +/- 0.4 to 1.5 +/- 0.7 (p < 0.0001) along with a gradient reduction (echo-Doppler) from 59 +/- 32 to 8 +/- 15 mmHg at rest, and from 120 +/- 42 to 28 +/- 32 mmHg with provocation (p < 0.0001 each). Exercise capacity improved from 94 +/- 51 to 119 +/- 40 watts (p = 0.001), and peak oxygen consumption from 18 +/- 4 to 21 +/- 6 ml/kg/min (p = 0.01). Younger age and higher outflow gradients at baseline and immediately after intervention were associated with a less favorable hemodynamic outcome. The degree of limitation of exercise capacity at baseline was the only predictor of symptomatic improvement. Conclusions Catheter-based septal ablation is an effective non-surgical technique for reducing symptoms and outflow gradients in HOCM. In contrast to a previous study, in this cohort of 312 patients there was no association between post-interventional enzyme release and hemodynamic success. Younger patients with high baseline gradients, however, tended to have a less favorable hemodynamic outcome with higher residual gradients.
引用
收藏
页码:864 / 873
页数:10
相关论文
共 33 条
[1]  
*ACC ESC, 2003, EUR HEART J, V24, P1965
[2]   Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy [J].
Boekstegers, P ;
Steinbigler, P ;
Molnar, A ;
Schwaiblmair, M ;
Becker, A ;
Knez, A ;
Haberl, R ;
Steinbeck, G .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (03) :846-853
[3]   Induced septal infarction - A new therapeutic strategy for hypertrophic obstructive cardiomyopathy [J].
Braunwald, E .
CIRCULATION, 1997, 95 (08) :1981-1982
[4]   Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy [J].
Chang, SM ;
Lakkis, NM ;
Franklin, J ;
Spencer, WH ;
Nagueh, SF .
CIRCULATION, 2004, 109 (07) :824-827
[5]   Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients [J].
Elliott, PM ;
Poloniecki, J ;
Dickie, S ;
Sharma, S ;
Monserrat, L ;
Varnava, A ;
Mahon, NG ;
McKenna, WJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (07) :2212-2218
[6]  
Faber L, 2003, Z KARDIOL, V92, P39, DOI 10.1007/s00392-003-0878-7
[7]   Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients [J].
Faber, L ;
Meissner, A ;
Ziemssen, P ;
Seggewiss, H .
HEART, 2000, 83 (03) :326-331
[8]   Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring [J].
Faber, L ;
Ziemssen, P ;
Seggewiss, H .
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2000, 13 (12) :1074-1079
[9]   Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy - Results with respect to intraprocedural myocardial contrast echocardiography [J].
Faber, L ;
Seggewiss, H ;
Gleichmann, U .
CIRCULATION, 1998, 98 (22) :2415-2421
[10]   Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy [J].
Flores-Ramirez, R ;
Lakkis, NM ;
Middleton, KJ ;
Killip, D ;
Spencer, WH ;
Nagueh, SF .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (01) :208-214